stockrowBristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.02%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Bristol Myers Squibb Company (BMY) Gross margin
Bristol Myers Squibb Company's gross margin over the twelve months to 30 September 2026 was 69.2%, down 1.8 percentage points from fiscal 2025 (71.1%). Over the past ten years it has ranged from 69.1% (fiscal 2019) to 78.6% (fiscal 2021); the current reading is higher than 36% of that period. That is below the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 71.1% | 0.00 |
| FY2024 | 71.1% | (5.16) |
| FY2023 | 76.2% | (1.80) |
| FY2022 | 78.0% | (0.53) |
| FY2021 | 78.6% | 6.26 |
| FY2020 | 72.3% | 3.21 |
| FY2019 | 69.1% | (2.24) |
| FY2018 | 71.3% | 0.29 |
| FY2017 | 71.1% | (3.37) |
| FY2016 | 74.4% | (1.97) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 68.3% | (3.00) |
| Jun 2026 | 71.3% | 1.06 |
| Mar 2026 | 70.2% | 2.98 |
| Dec 2025 | 67.2% | (4.65) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG compare | 74.9% |
| SNY Sanofi compare | 73.4% |
| PFE Pfizer Inc. compare | 73.4% |
| GSK GSK PLC Sponsored ADR compare | 72.6% |
| AMGN Amgen Inc. compare | 70.9% |
| BMY Bristol Myers Squibb Company | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement